Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal

Table 4 Risk estimation for NAFLD in association with pre-existing co-morbid conditions

	NAFLD	Control	X²	RR	p
Diabetes (FBS ≥ 126 mg/dl)	(n)	(n)
Yes	36	9	5.621	1.68	0.016
No	183	201
Cardiovascular Risk (TC/HDL-C > 5)
Yes	135	9	52.721	3.18	< 0.001
No	84	201
Hyperurecemia (UA > 7.5 mg/dl)
Yes	33	15	2.259	1.41	0.107
No	186	195
Central Obesity (WC > 94 cm(M),> 80 cm(F))
Yes	123	24	34.909	2.50	< 0.001
No	96	186

Bold represents statistically significant values (p < 0.05). RR- relative risk, n- the number of population

ISSN: 1471-230X